Clin2
NCT06957691Possibly a fitRecruiting

Fezolinetant for hot flashes in men on hormone therapy

Prostate CancerProstate Cancer (Adenocarcinoma)Prostate Cancer Metastatic DiseaseProstate Cancer RecurrentProstate CarcinomaProstate NeoplasmProstate AdenocarcinomaProstate Cancer With Bone Metastasis

Part of Cancer, Genetic & congenital, Hormones & metabolism, Kidney & urinary clinical trials.

This study tests a medication called fezolinetant to see if it reduces hot flashes in men undergoing hormone therapy for prostate cancer. If you experience frequent hot flashes, this treatment might help alleviate them.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
60 people
Ages
40 years and older
Study type
Interventional

Who can take part

  • You must be a man diagnosed with prostate cancer.
  • You must be 40 years of age or older.
  • You must be receiving androgen deprivation therapy (hormone therapy to lower testosterone).
  • You must have at least 5 moderate to severe hot flashes per day or 35 per week.
  • You must be willing to abstain from alcohol for the duration of the study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07568236Not yet recruiting· Phase 2
Fezolinetant for hot flashes in men on prostate cancer treatment

This trial tests a new medication called fezolinetant to reduce hot flashes (sudden feelings of intense heat) in men receiving hormone therapy for prostate cancer. Hot flashes are a common side effect of this treatment, and this study aims to see if fezolinetant can help relieve them.

Shatin
NCT06972875Recruiting· Phase 2
Testing a hot flash pill for men on prostate cancer therapy

This trial tests a non-hormonal pill called fezolinetant to reduce hot flashes in men with prostate cancer who are on hormone therapy. If you have daily, bothersome hot flashes, this study may help you find relief.

Burlington, Vermont
NCT07602530Recruiting
Tracking Hot Flash Treatment Outcomes in Canadian Women

This study follows women in Canada who are starting fezolinetant, a new medication for hot flashes during menopause. Researchers will track how well it works and how you feel while using it in your regular doctor's care.

Montreal
NCT07783282Not yet recruiting· Phase 1
Study of drug interactions in men with prostate cancer and healthy volunteers

This study is testing how a new drug (fezolinetant) is processed in the body when given to men with prostate cancer and healthy men. It helps see if other prostate cancer drugs interfere with fezolinetant, which might be used for other conditions in the future.

NCT07729150Not yet recruiting
Wearable device study for hormone therapy hot flashes

This study tests whether a wearable cooling or heating device can help reduce hot flashes caused by hormone therapy for prostate cancer. You will use the device for 12 weeks and report how often and how much your hot flashes bother you.

NCT07335224Recruiting
Acupuncture for hot flashes in men with prostate cancer

This trial tests if acupuncture can reduce the daily discomfort from hot flashes caused by hormone therapy (androgen deprivation therapy) for prostate cancer. It may help men who are bothered by frequent or intense hot flashes find better relief.

Fairfax, Virginia

Hear when a new Prostate cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.